A Systematic Review of Symptoms for the Diagnosis of Ovarian Cancer
- PMID: 26541098
- DOI: 10.1016/j.amepre.2015.09.023
A Systematic Review of Symptoms for the Diagnosis of Ovarian Cancer
Abstract
Context: Ovarian cancer is common and has significant morbidity and mortality, partly because it is often diagnosed at a late stage. This study sought to determine the accuracy of individual symptoms and combinations of symptoms for the diagnosis of ovarian cancer.
Evidence acquisition: MEDLINE was searched, identifying 2,492 abstracts, reviewing 71 articles in full, and ultimately identifying 17 studies published between 2001 and 2014 that met the inclusion criteria. Data were abstracted by two researchers, and quality was assessed using the QUADAS-2 criteria adapted to the study question. Bivariate random effects meta-analysis was used where possible, and heterogeneity and threshold effects were explored using receiver operating characteristic curves. Data were analyzed in 2015.
Evidence synthesis: Most studies were at high risk of bias, primarily because of case-control design or differential verification bias. The highest positive likelihood ratios (LRs+) were found for presence of abdominal mass (LR+, 30.0); abdominal distension or increased girth (LR+, 16.0); abdominal or pelvic pain (LR+, 10.4); abdominal or pelvic bloating (LR+, 9.3); loss of appetite (LR+, 9.2); and a family history of ovarian cancer (LR+, 7.5). No symptoms were helpful at ruling out ovarian cancer when absent. The Ovarian Cancer Symptom Index was validated in five studies and (after excluding one outlier with different inclusion criteria) was 63% sensitive and 95% specific (LR+, 12.6; LR-, 0.39). Two other symptom scores had not been validated prospectively.
Conclusions: Several individual signs and symptoms significantly increase the likelihood of ovarian cancer when present. More work is needed to validate decision rules and develop new decision support tools integrating risk factors, symptoms, and possibly biomarkers to identify women at increased ovarian cancer risk.
Copyright © 2016 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Spontaneous Subarachnoid Hemorrhage: A Systematic Review and Meta-analysis Describing the Diagnostic Accuracy of History, Physical Examination, Imaging, and Lumbar Puncture With an Exploration of Test Thresholds.Acad Emerg Med. 2016 Sep;23(9):963-1003. doi: 10.1111/acem.12984. Epub 2016 Sep 6. Acad Emerg Med. 2016. PMID: 27306497 Free PMC article. Review.
-
Diagnostic Accuracy of History, Physical Examination, Laboratory Tests, and Point-of-care Ultrasound for Pediatric Acute Appendicitis in the Emergency Department: A Systematic Review and Meta-analysis.Acad Emerg Med. 2017 May;24(5):523-551. doi: 10.1111/acem.13181. Acad Emerg Med. 2017. PMID: 28214369 Review.
-
Diagnostic test accuracy of nutritional tools used to identify undernutrition in patients with colorectal cancer: a systematic review.JBI Database System Rev Implement Rep. 2015 May 15;13(4):141-87. doi: 10.11124/jbisrir-2015-1673. JBI Database System Rev Implement Rep. 2015. PMID: 26447079 Review.
-
Accuracy of Physical Examination, Ankle-Brachial Index, and Ultrasonography in the Diagnosis of Arterial Injury in Patients With Penetrating Extremity Trauma: A Systematic Review and Meta-analysis.Acad Emerg Med. 2017 Aug;24(8):994-1017. doi: 10.1111/acem.13227. Acad Emerg Med. 2017. PMID: 28493614 Review.
-
History, Physical Examination, Laboratory Testing, and Emergency Department Ultrasonography for the Diagnosis of Acute Cholecystitis.Acad Emerg Med. 2017 Mar;24(3):281-297. doi: 10.1111/acem.13132. Acad Emerg Med. 2017. PMID: 27862628 Review.
Cited by
-
Circulating Cell Free DNA as the Diagnostic Marker for Ovarian Cancer: A Systematic Review and Meta-Analysis.PLoS One. 2016 Jun 2;11(6):e0155495. doi: 10.1371/journal.pone.0155495. eCollection 2016. PLoS One. 2016. PMID: 27253331 Free PMC article. Review.
-
The Use of Lipid-based Nanocarriers to Improve Ovarian Cancer Treatment: An Overview of Recent Developments.Curr Pharm Biotechnol. 2024;25(17):2200-2217. doi: 10.2174/0113892010279572240126052844. Curr Pharm Biotechnol. 2024. PMID: 38357950 Review.
-
A BRCA1 Splice Site Variant Responsible for Familial Ovarian Cancer in a Han-Chinese Family.Curr Med Sci. 2022 Jun;42(3):666-672. doi: 10.1007/s11596-022-2527-2. Epub 2022 Mar 15. Curr Med Sci. 2022. PMID: 35290602
-
FAPhigh α-SMAlow cancer-associated fibroblast-derived SLPI protein encapsulated in extracellular vesicles promotes ovarian cancer development via activation of PI3K/AKT and downstream signaling pathways.Mol Carcinog. 2022 Oct;61(10):910-923. doi: 10.1002/mc.23445. Epub 2022 Jul 8. Mol Carcinog. 2022. PMID: 35801406 Free PMC article.
-
Nanotechnology-enhanced immunotherapy for metastatic cancer.Innovation (Camb). 2021 Oct 14;2(4):100174. doi: 10.1016/j.xinn.2021.100174. eCollection 2021 Nov 28. Innovation (Camb). 2021. PMID: 34766099 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous